Nicotinic acid mononucleotide trietlamine is formed from nicotinic acid (NA) via the nicotinic acid phosphoribosyltransferase in the biosynthesis of NAD+. Nicotinate mononucleotide trietlamine is a substrate for nicotinamide mononucleotide/Nicotinic acid mononucleotide adenylyltransferase[1][2].
[1]. Khan JA, et al. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007 May;11(5):695-705.
[2]. O'Hara JK, et al. Targeting NAD+ metabolism in the human malaria parasite Plasmodium falciparum. PLoS One. 2014 Apr 18;9(4):e94061.
















